Treat with foresight
mCNV

mCNV

Strong, rapid, and sustained visual

gains over 48 weeks1

MOST VISUAL GAINS WERE ACHIEVED WITH 1 OR 2 INJECTIONS1

EYLEA®-treated patients had a mean gain of +12.1 letters and 39% gained ≥3 lines at Week 24,increasing to +13.5 letters and 50% with ≥3 lines gained at Week 481

WEEK 48

MEAN GAIN
MEAN CHANGE

Mean change in BCVA through Week 1001

MEAN CHANGE

EYLEA 2 mg administered at baseline and monthly up to Week 44 if mCNV persisted or recurred; n=90.

Sham injection administered at baseline up to Week 20 regardless of whether re-treatment criteria were fulfilled or not, followed by EYLEA 2 mg at Week 24 and monthly if disease persisted/recurred up to Week 44; n=31.

  • mCNV lesion size was reduced by >50% from baseline to Week 24 in the early EYLEA treatment group1
  • Lesion size almost doubled in the delayed treatment group1
  • mCNV leakage was resolved by Week 48 in 86% of early EYLEA-treated patients vs. 67% in the delayed treatment group1
DOSING
MOA

BCVA, best-corrected visual acuity; mCNV, myopic choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; RCT, randomized controlled trial; VA, visual acuity

References:

  • Ikuno Y, Ohno-Matsui K, Wong TY et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study. Ophthalmology. 2015;122(6):1220–1227.
  • EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.

This website contains information on EYLEA® (aflibercept solution for injection) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK. In countries outside the EU the local Product Information applies.

PP-EYL-ALL-0513-1. Last updated on 29/02/2020